The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice
- 6 June 2002
- journal article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 11 (4), 311-317
- https://doi.org/10.1002/pds.709
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Secondary prevention in 24 431 patients with coronary heart disease: survey in primary careBMJ, 2001
- A survey of validity and utility of electronic patient records in a general practiceBMJ, 2001
- Sex inequalities in ischaemic heart disease in general practice: cross sectional surveyBMJ, 2001
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE surveyEuropean Heart Journal, 1999
- beta Blockade after myocardial infarction: systematic review and meta regression analysisBMJ, 1999
- Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial InfarctionCirculation, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- β-Blockers and Sudden Cardiac DeathAnnals of Internal Medicine, 1995
- ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarctionThe Lancet, 1995